April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Comparison of Spectral Domain OCT Volumetric Analysis Before and After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Author Affiliations & Notes
  • V. B. Voleti
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • L.-S. B. Leung
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • R. Iranmanesh
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • L. V. Del Priore
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • G. R. Barile
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • W. M. Schiff
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • S. Chang
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • H. F. Fine
    Department of Ophthalmology, Edward Harkness Eye Institute of Columbia University, New York, New York
  • Footnotes
    Commercial Relationships  V.B. Voleti, None; L.-S.B. Leung, None; R. Iranmanesh, None; L.V. Del Priore, None; G.R. Barile, None; W.M. Schiff, None; S. Chang, None; H.F. Fine, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3252. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. B. Voleti, L.-S. B. Leung, R. Iranmanesh, L. V. Del Priore, G. R. Barile, W. M. Schiff, S. Chang, H. F. Fine; Comparison of Spectral Domain OCT Volumetric Analysis Before and After Intravitreal Bevacizumab Injection for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3252.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To measure response to intravitreal bevacizumab using spectral domain OCT (SD-OCT) volumetric and subfield thickness analysis in patients with diabetic macular edema (DME).

Methods: : Retrospective review of patients with DME who underwent SD-OCT examination in conjunction with a complete ophthalmic exam at baseline and then again 3-5 weeks following intravitreal bevacizumab injection. Patients were excluded if they had received laser photocoagulation, injection of any pharmacologic agent, or intraocular surgery ≤ 3 months before injection. The primary outcome measures were change in macular volume, average retinal thickness, and the 9 subfield retinal thicknesses as measured by the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA). A paired student t-test was used to compare patients before and after injection, as well as to non-diabetic controls.

Results: : Retinal thickness was significantly elevated among diabetic eyes (n = 14) prior to injection compared to control eyes (n = 18) [mean retinal volume 12.2 ± 2.4 mm3 vs. 9.5 ± 0.5 mm3 (p=0.00005), mean average retinal thickness 340 ± 65 µm vs. 265 ± 14 µm (p = 0.00004), and mean central macular thickness 480 ± 191 µm vs. 245 ± 23 µm (p = 0.00001)]. Following bevacizumab injection, there was a non-significant mean reduction in thickness for the central macular subfield (480 ± 191 to 455 ± 187, p = 0.40), the peripheral superior subfield (313 ± 49 to 299 ± 54, p = 0.19), the central superior subfield (407 ± 119 to 397 ± 99, p = 0.51), and the central temporal subfield (438 ± 129 to 426 ± 136, p = 0.40). There was also a non-significant improvement in mean visual acuity following injection (0.63 to 0.55 logMAR, p = 0.17). Change in macular volume following injection was not statistically different (pre-injection 12.2 ± 2.4 mm3 vs. post-injection 12.5 ± 2.9 mm3, p= 0.40). The mean change in average retinal thickness and the remaining subfield thicknesses were also not significant.

Conclusions: : The study demonstrates that quantification of DME using SD-OCT yields statistically significant differences in volume and thickness parameters compared to controls. Following bevacizumab injection, there was a non-significant reduction in central macular thickness that correlated with a modest improvement in visual acuity. Overall, however, retinal volume and thickness parameters did not significantly change after a single injection of bevacizumab in patients with DME. Explanations for this observation include insufficient dosage or the involvement of non-VEGF factors in disease pathogenesis.

Keywords: imaging/image analysis: clinical • edema • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×